Annovis Bio Regains Compliance with NYSE Listing Standards

Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for Alzheimer's and Parkinson's diseases, announced it has regained compliance with the New York Stock Exchange's continued listing standards. The company implemented corrective measures to restore its market capitalization and stockholders' equity above required thresholds, allowing its common stock to continue trading on the NYSE under the ticker symbol ANVS.

The announcement, detailed in a press release on MissionIR, underscores Annovis's commitment to maintaining its listing on the premier U.S. exchange. Regaining compliance is crucial for the company as it advances its lead drug candidate, buntanetap, through Phase 3 clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD).

Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.

Headquartered in Malvern, Pennsylvania, Annovis Bio is focused on developing treatments for neurodegenerative diseases. The company's approach targets multiple toxic proteins simultaneously, which could offer a more comprehensive therapeutic strategy compared to single-target therapies. With buntanetap in Phase 3 trials, positive results could significantly impact the treatment landscape for AD and PD, affecting millions of patients worldwide.

Regaining NYSE compliance not only ensures continued trading without disruption but also reinforces investor confidence in the company's financial stability and operational strategy. The NYSE requires listed companies to maintain certain market capitalization and stockholders' equity levels, and Annovis's ability to meet these standards reflects its financial health. For more information about Annovis Bio, visit www.annovisbio.com.

This development is particularly important as Annovis prepares for upcoming clinical milestones. The company's progress in neurodegenerative disease research holds promise for patients who currently have limited treatment options. By maintaining its NYSE listing, Annovis can continue to access capital markets to fund its research and development activities.

For the latest news and updates relating to Annovis Bio, interested parties can visit the company's newsroom at https://ibn.fm/ANVS.